ArticleCancer cell international2025
NSC777201 exhibits anticancer activity against colorectal cancer cells by inducing multiple types of cell death.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) ranks as the third most prevalent cancer globally, necessitating the development of novel therapeutic strategies. NSC777201, a multi-targeted anticancer agent, has demonstrated efficacy in various cancers, including prostate cancer, non-small cell lung cancer (NSCLC), glioblastoma (GBM), and pancreatic ductal adenocarcinoma (PDAC). However, its potential in CRC remains unexplored.
methodsIn this study, National Cancer Institute (NCI)-60 cancer cell panel screening identified CRC as the most sensitive to NSC777201 treatment. We further validated its in vitro anticancer effects in four CRC cell lines (HCT116, HT29, RKO, and DLD-1) and its in vivo efficacy using HCT116 tumor xenografts in nude mice. Mechanistic studies included analyses of epidermal growth factor receptor (EGFR) and MET protein inhibition and investigations into cell death pathways triggered by NSC777201.
resultsNSC777201 exhibited potent in vitro and in vivo anticancer activities against human CRC cells. NSC777201 inhibited expressions of the EGFR and MET proteins in CRC cells, consistent with findings in other cancers. Mechanistic studies revealed that NSC777201 induced CRC cell death through autophagy, ferroptosis, and ferritinophagy. Moreover, NSC777201-induced ferroptosis was partially dependent on upregulation of 7-dehydrocholesterol (DHC) reductase (DHCR7) and subsequent reduction of the endogenous ferroptosis suppressor, 7-DHC.
conclusionsThese findings highlight NSC777201’s robust anticancer activity in CRC, mediated by multiple cell death pathways, offering promising therapeutic potential for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.